Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

When the patient, we do know, that in IDH mutated patient that their tumor is dividing more, so a higher mutational index. So, grade 3 or grade 4 patients that we still need to think in those ...